Privia Health Group (PRVA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
The annual meeting is scheduled for May 20, 2026, via virtual webcast, with voting available online, by phone, or mail for shareholders of record as of March 23, 2026.
Key proposals include electing three Class I directors, an advisory vote on executive compensation, and ratification of the external auditor.
The board emphasizes robust governance, regular board refreshment, and strong shareholder engagement, including recent elimination of supermajority voting requirements.
The company highlights significant progress in corporate responsibility, cybersecurity, employee engagement, and environmental stewardship.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class I directors (Nancy Cocozza, David King, Francis Soistman) to serve until 2029.
Advisory (non-binding) vote on executive compensation (say-on-pay) is included.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is proposed.
Shareholder proposals for the 2027 meeting must be submitted by December 3, 2026.
Board of directors and corporate governance
The board is classified into three classes with staggered terms; nine directors serve across Class I, II, and III.
Board leadership is separated between CEO and independent Chair.
All required committees (Audit, Compensation, Nominating and Corporate Governance, Compliance) are fully independent.
Regular board and committee self-evaluations, annual CEO performance reviews, and succession planning are in place.
No poison pill is in effect; outside board service is limited for independent directors.
Latest events from Privia Health Group
- Strong growth, profitability, and scale in value-based care with robust financial outlook for FY'26.PRVA
Investor presentation - Q2 2026 revenue up 21.4%, net income up 236.7%, and adjusted EBITDA up 29.1%.PRVA
Q2 2026 - Q1 revenue up 25.8%, adjusted EBITDA up 36.3%, and guidance raised for attributed lives.PRVA
Q1 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.PRVA
Proxy filing - 2025 outperformance and 2026 guidance highlight robust growth, cash flow, and strategic expansion.PRVA
Q4 2025 - Q3 2025 revenue up 32.5%, net income up 94.1%, and FY 2025 guidance raised after strong growth.PRVA
Q3 2025 - Raised 2024 guidance after strong Q3 growth, robust cash flow, and Indiana market entry.PRVA
Q3 2024 - Q2 2024 delivered strong growth, raised guidance, and maintained a robust cash position.PRVA
Q2 2024 - Tech-enabled platform drives profitable growth and high retention in value-based care.PRVA
The 44th Annual William Blair Growth Stock Conference